Accessibility Menu
Bioventus logo

Bioventus(NASDAQ) BVS

Market Cap$976.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-26%
5 Year-7%
1 Year+99%
1 Month+19%
$14.54
+1.68%
+0.24Today
Bioventus last closing stock price
MetricPriceDate
Last closeUSD 14.302026-08-18
Bioventus stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.25%USD 13.852026-08-11
1 month+18.57%USD 12.062026-07-17
3 month+30.71%USD 10.942026-05-20
Year to date+92.2%USD 7.442025-12-31
1 year+99.16%USD 7.182025-08-18
3 year+226.48%USD 4.382023-08-18
5 year-7.32%USD 15.432021-08-19
Since inception-25.56%USD 19.212021-02-11

Bioventus Financials at a Glance

Market Cap

$976.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$581.85M

Net Income (TTM)

$54.46M

EPS (TTM)

$0.78

P/E Ratio

18.44

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$14.54

Volume

172,608.487

Open

$14.35

Previous Close

$14.30

Daily Range

$14.35 - $14.92

52-Week Range

$6.26 - $15.89

Estimated Earnings Date

Nov 3, 2026

BVS News

doctor scientist microscope gloves mask (1)

Why Shares of Bioventus Fell 14% on Wednesday

James HalleyNov 9, 2022
Knee x-ray

Why Bioventus Stock Is Sinking Today

Keith SpeightsApr 4, 2022
Physical therapy medical professional examining knee of patient

Will a Powerful Acquisition Make This Early 2021 IPO a Buy?

Jeffrey LittleAug 17, 2021

BVS: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bioventus

Bioventus makes medical tools that help people heal from bone and joint pain. These products help patients recover from injuries and surgeries without always needing major operations. The company helps doctors treat conditions like knee arthritis and broken bones.

Three Ways to Heal

  • Pain Treatments: Hyaluronic acid (a natural joint lubricant) injections for knee pain and nerve stimulation systems used for chronic pain relief.
  • Surgical Solutions: Bone graft substitutes and ultrasonic cutting tools used to help bones grow together after spine or orthopedic surgery.
  • Restorative Therapies: Ultrasound bone healing systems designed to help fractures heal when the body's natural healing process stalls.

New Deals and Clearances

  • Entered an agreement with Apex Biologix in 2025 to serve as the exclusive U.S. distributor for their platelet-rich plasma system.
  • Launched StimTrial and Talismann nerve stimulation products in select U.S. markets during the third quarter of 2025.
  • Received FDA approval in the second quarter of 2024 for a specialized cannula-based delivery system for its OSTEOAMP bone graft product.
  • Obtained expanded FDA clearance in 2023 for SIGNAFUSE synthetic bone graft for use in spinal procedures.

Innovation and Reach

Bioventus manages its business through U.S. and International segments, with the U.S. market accounting for 88% of net sales in 2025. Its portfolio focuses on minimally invasive therapies that provide alternatives to traditional surgery or opioid-based pain management.

Looking at the Numbers

  • Net income reached $14.8 million in Q4 2025, up from a loss of $156,000 in Q4 2024.
  • Operating income grew to $21.7 million in Q4 2025, an increase of 171.9% from the previous year.
  • Free cash flow hit $37.4 million in Q4 2025, up 99.4% from Q4 2024.
  • Revenue was $157.9 million in Q4 2025, up 2.8% from $153.6 million in the prior year period.

Bottom Line

Bioventus has evolved from a specialized bone-healing firm into a provider of diverse pain management and surgical technologies. Its expanded product range allows the company to support patients throughout the entire cycle of orthopedic care and recovery.

AI Generated • May 4, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

930

CEO

Robert E. Claypoole, MBA

Website

www.bioventus.com

Headquarters

Durham, NC 27703, US

BVS Financials

Key Financial Metrics (TTM)

Gross Margin

68.00%

Operating Margin

10.63%

Net Income Margin

9.36%

Return on Equity

28.39%

Return on Capital

11.82%

Return on Assets

8.09%

Earnings Yield

5.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$976.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.31M

Volume

172.61K

Avg. Volume

764.55K

Financials (TTM)

Gross Profit

$395.64M

Operating Income

$61.83M

EBITDA

$92.82M

Operating Cash Flow

$96.87M

Capital Expenditure

-$2.59M

Free Cash Flow

$94.29M

Cash & ST Invst.

$29.46M

Total Debt

$263.75M

Bioventus Performance Analysis

Bioventus annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 512,117,00018.8%
20232023-12-31USD 512,345,0000.0%
20242024-12-31USD 573,280,00011.9%
20252025-12-31USD 568,087,000-0.9%
Bioventus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-27-6.1%
Q42025-12-3113.9%
Q12026-03-28-16.3%
Q22026-06-2716.0%
Bioventus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.59N/A
20232023-12-31USD -2.49-3.5%
20242024-12-31USD -0.56-77.6%
20252025-12-31USD 0.33N/A
Bioventus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-27-58.4%
Q42025-12-31358.5%
Q12026-03-28-78.8%
Q22026-06-27956.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$153.21M

+3.8%

Gross Profit

$105.67M

+5.0%

Gross Margin

68.97%

N/A

Market Cap

$976.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.03M

N/A

Employees

950

N/A

Net Income

$33.44M

+348.3%

EBITDA

$19.38M

-35.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$29.46M

-10.5%

Total Debt

$263.75M

-22.7%

Accounts Receivable

$138.41M

+4.6%

Inventory

$79.81M

-17.3%

Long Term Debt

$240.86M

-19.1%

Short Term Debt

$22.89M

-47.2%

Return on Assets

8.09%

N/A

Return on Invested Capital

11.87%

N/A

Free Cash Flow

$18.91M

-25.1%

Operating Cash Flow

$19.87M

-23.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CBLLCeriBell, Inc.
$25.04+3.41%
AVNSAvanos Medical, Inc.
$24.99+0.04%
VREXVarex Imaging Corporation
$18.49+0.17%
KIDSOrthoPediatrics Corp.
$26.39+3.51%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$140.50+1.23%
IBITiShares Bitcoin Trust
$38.79+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$9.26+0.06%
INTCIntel
$93.22-0.04%

Questions About BVS

What is the current price of Bioventus?

Bioventus is trading at $14.55 per share.

What is the 52-week range for Bioventus?

Over the past 52 weeks, Bioventus has traded between $6.26 and $15.89.

How much debt does Bioventus have?

As of the most recent reporting period, Bioventus reported total debt of $263.75M.

How much cash does Bioventus have on hand?

Bioventus reported $29.46M in cash and cash equivalents in its most recent financial results.

What is Bioventus’s dividend yield?

Bioventus does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services